DK1356052T3 - Produktion af hele antistoffer i prokaryotiske celler - Google Patents

Produktion af hele antistoffer i prokaryotiske celler

Info

Publication number
DK1356052T3
DK1356052T3 DK01993297T DK01993297T DK1356052T3 DK 1356052 T3 DK1356052 T3 DK 1356052T3 DK 01993297 T DK01993297 T DK 01993297T DK 01993297 T DK01993297 T DK 01993297T DK 1356052 T3 DK1356052 T3 DK 1356052T3
Authority
DK
Denmark
Prior art keywords
production
prokaryotic cells
whole antibodies
antibodies
prokaryotic expression
Prior art date
Application number
DK01993297T
Other languages
Danish (da)
English (en)
Inventor
Laura C Simmons
Laura Klimowski
Dorothea E Reilly
Daniel G Yansura
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22971295&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1356052(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1356052T3 publication Critical patent/DK1356052T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01993297T 2000-12-14 2001-12-13 Produktion af hele antistoffer i prokaryotiske celler DK1356052T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25616400P 2000-12-14 2000-12-14
PCT/US2001/048691 WO2002061090A2 (fr) 2000-12-14 2001-12-13 Anticorps produits de maniere procaryote et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
DK1356052T3 true DK1356052T3 (da) 2008-12-08

Family

ID=22971295

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01993297T DK1356052T3 (da) 2000-12-14 2001-12-13 Produktion af hele antistoffer i prokaryotiske celler

Country Status (11)

Country Link
EP (1) EP1356052B1 (fr)
JP (1) JP4309656B2 (fr)
KR (1) KR100879194B1 (fr)
AT (1) ATE405650T1 (fr)
AU (1) AU2002245142B2 (fr)
CA (1) CA2430182C (fr)
DE (1) DE60135498D1 (fr)
DK (1) DK1356052T3 (fr)
ES (1) ES2312494T3 (fr)
MX (1) MXPA03005273A (fr)
WO (1) WO2002061090A2 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ530852A (en) * 2001-08-27 2006-11-30 Genentech Inc Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells
EP1908769A1 (fr) * 2001-08-27 2008-04-09 Genentech, Inc. Système d'expression d'anticorps et ensemble
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7351803B2 (en) 2002-05-30 2008-04-01 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
EP2292637B1 (fr) 2002-09-06 2016-01-06 Genentech, Inc. Procédé d'extraction de protéines
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
JP2005241389A (ja) * 2004-02-25 2005-09-08 Ochiyanomizu Jiyoshi Univ 蛍光標識糖鎖の特異的固定化試薬および固定化方法
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
EP1774017B1 (fr) 2004-07-26 2013-05-15 Pfenex Inc. Procede permettant d'ameliorer l'expression d'une proteine par mise au point d'une souche par genie genetique
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2845865A1 (fr) 2004-11-12 2015-03-11 Xencor Inc. Variantes Fc avec liaison altérée en FcRn
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
CA2625998C (fr) 2005-10-06 2015-12-01 Xencor, Inc. Anticorps anti-cd30 optimises
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
WO2008036688A2 (fr) 2006-09-18 2008-03-27 Xencor, Inc. Anticorps optimisés ciblant l'antigène hm1.24
ATE465241T1 (de) * 2006-09-22 2010-05-15 Wacker Chemie Ag Verfahren zur fermentativen herstellung von proteinen
DE502006009060D1 (de) 2006-09-22 2011-04-21 Wacker Chemie Ag Verfahren zur fermentativen Herstellung von Antikörpern
DK1905839T4 (da) * 2006-09-22 2019-10-07 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af proteiner
WO2008134461A2 (fr) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Procédé pour rapidement cribler des hôtes microbiens et identifier certaines souches ayant un rendement et/ou une qualité d'expression des protéines hétérologues améliorés
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US20100168392A1 (en) * 2007-08-10 2010-07-01 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc FC variants with modified binding to FCRN
JP5785941B2 (ja) 2009-06-17 2015-09-30 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｖｅｇｆ抗体とその使用
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
HUE040306T2 (hu) 2009-09-24 2019-03-28 Ucb Biopharma Sprl Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént
AU2010314981B2 (en) 2009-11-05 2015-07-02 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
GB201000590D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000588D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
HUE035674T2 (en) * 2011-07-13 2018-05-28 Ucb Biopharma Sprl Bacterial host strains expressing recombinant DSBC
GB201208367D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
WO2013181586A2 (fr) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Méthodes associées au bevacizumab
WO2013181575A2 (fr) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Méthodes associées au denosumab
US20150353940A1 (en) * 2013-08-05 2015-12-10 Absci, Llc Vectors for use in an inducible coexpression system
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
PL3116999T3 (pl) 2014-03-14 2021-12-27 F.Hoffmann-La Roche Ag Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
CN106661588B (zh) 2014-07-09 2020-11-06 鲁平有限公司 双顺反子细菌表达***
AU2015342961B2 (en) * 2014-11-05 2021-08-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
JP6770966B2 (ja) * 2014-11-05 2020-10-21 ジェネンテック， インコーポレイテッド 細菌における２鎖タンパク質の生成方法
JP6865689B2 (ja) 2015-03-06 2021-04-28 ジェネンテック， インコーポレイテッド 超精製ＤｓｂＡ及びＤｓｂＣ、ならびにそれらの作製及び使用方法
KR20180048731A (ko) * 2015-08-20 2018-05-10 제넨테크, 인크. 재조합 폴리펩티드를 제조하기 위한 fkpa의 정제 및 그의 용도
CN109312408B (zh) 2016-05-17 2022-12-23 豪夫迈·罗氏有限公司 用于诊断和供免疫疗法中使用的基质基因签名
CN109563124A (zh) 2016-06-17 2019-04-02 豪夫迈·罗氏有限公司 多特异性抗体的纯化
GB201617270D0 (en) * 2016-10-11 2016-11-23 Argen-X N V And Fairjourney Biologics Triple vector for expressing antibody molecules in full therapeutic format
PE20210915A1 (es) * 2017-11-27 2021-05-19 4D Molecular Therapeutics Inc Capsides variantes de virus adenoasociados y su uso para inhibir la angiogenesis
CN110003328B (zh) * 2018-01-05 2022-04-19 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
EP3877407A1 (fr) 2018-11-05 2021-09-15 F. Hoffmann-La Roche AG Procédés de production de protéines bicaténaires dans des cellules hôtes procaryotes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341235C (fr) * 1987-07-24 2001-05-22 Randy R. Robinson Assemblage modulaire de genes d'anticorps, anticorps prepares de cette facon, ainsi que leur usage
WO1993008300A1 (fr) * 1991-10-18 1993-04-29 The University Of Calgary Vecteurs d'expression/secretion destines a la production de fragments de fv biologiquement actifs
US20020037558A1 (en) * 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5840523A (en) * 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5747662A (en) * 1995-03-01 1998-05-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung

Also Published As

Publication number Publication date
JP2004530419A (ja) 2004-10-07
WO2002061090A2 (fr) 2002-08-08
CA2430182C (fr) 2011-01-25
DE60135498D1 (de) 2008-10-02
WO2002061090A3 (fr) 2003-08-21
EP1356052A2 (fr) 2003-10-29
MXPA03005273A (es) 2003-09-25
KR20030074654A (ko) 2003-09-19
ATE405650T1 (de) 2008-09-15
AU2002245142B2 (en) 2007-07-05
EP1356052B1 (fr) 2008-08-20
ES2312494T3 (es) 2009-03-01
JP4309656B2 (ja) 2009-08-05
CA2430182A1 (fr) 2002-08-08
KR100879194B1 (ko) 2009-01-16

Similar Documents

Publication Publication Date Title
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
DE60224291D1 (de) System zur antikörperexpression und- synthese
ATE251942T1 (de) Stapelbare statische mischelemente
GB0411186D0 (en) Biological products
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
BR0203650A (pt) Estentor de auto-articulação
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
EP1461081A4 (fr) Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon
ATE444308T1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
DK1513937T3 (da) Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
DK0814827T3 (da) Karendotel-vækstfaktor-B
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
NO20052363L (no) Interferon-alfa polypeptider og konjugater
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
EP1557462A3 (fr) Cellules d'induction de l'acceptance d'un transplant d'origine monocytique et leur préparation et utilisation
ATE419277T1 (de) Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen
WO1999045098A3 (fr) Apport de proteines a des cellules eucaryotes au moyen de la yersinia recombinee
IN266744B (fr)
ES2177316T3 (es) Anticuerpos humanos antifacotores ix/ixa.
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
EP2083018A3 (fr) Compositions et procédés associés à STOP-1
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje